Systolic Pulmonary Arterial Pressure Predicts Mortality Risk in Systemic Sclerosis Patients

Author: Christin Melton, ELS, CMPP
Date Published: February-2015
Source: Rare Disease Report

Findings from the multinational European League Against Rheumatism Scleroderma Trial and Research (EUSTAR) study show that systolic pulmonary arterial pressure (sPAP) is an important prognostic factor for patients with systemic sclerosis (or scleroderma). More specifically, lead author Eric Hachulla, MD, National Reference Center for Scleroderma, Department of Internal Medicine, University of Lille Nord de France, told Rare Disease Report that “an sPAP above 36 mm Hg is an independent predictive factor of death” in this patient population.